ChemicalBook CAS DataBase List 2886-65-9

2886-65-9

Name	7-Chloro-5-(2-fluoro-phenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one
CAS	2886-65-9
EINECS(EC#)	220-748-3
Molecular Formula	C15H10ClFN2O
MDL Number	MFCD00083443
Molecular Weight	288.7
MOL File	2886-65-9.mol

Synonyms

5-(2-FLUOROPHENYL)-7-CHLORO-1,4-BENZODIAZEPIN-2-ONE 7-CHLORO-5-(2-FLUOROPHENYL)-1,3-DIHYDRO-1,4-BENZODIAZEPIN-2-ONE 7-CHLORO-5-(2-FLUOROPHENYL)-1,3-DIHYDRO-2H-1,4-BENZODIAZEPIN-2-ONE 7-CHLORO-5-(2-FLUOROPHENYL)-1,3-DIHYDRO-BENZO[E][1,4]DIAZEPIN-2-ONE DESALKYLFLURAZEPAM NORFLUDIAZEPAM 1,3-dihydro-7-chloro-5-(2-fluorophenyl)-2h-4-benzodiazepin-2-one 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-5-(2-fluorophenyl)- 2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-fluorophenyl)-1,3-dihydro- 2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(o-fluorophenyl)-1,3-dihydro- 7-chloro-5-(o-fluorophenyl)-1,3-dihydro-2h-4-benzodiazepin-2-one cm7116 Dealkylflurazepam Descarbethoxyloflazepate Flurazepam M (des-alkyl) Flurazepam M (N-1-des-alkyl) Flurazepam, des-alkyl N-1-desalkyl-flurazepam N-Desalkyl-2-oxoquazepam N-Desalkylflurazepam

Chemical Properties

Appearance	Light Yellow Solid
Melting point	204-206°C
Boiling point	454.0±45.0 °C(Predicted)
density	1.39±0.1 g/cm3(Predicted)
Fp	9℃
storage temp.	Sealed in dry,Room Temperature
solubility	Chloroform (Slightly), Methanol (Slightly)
form	A neat solid
pka	11.55±0.70(Predicted)
color	White to off-white
Usage	The major human metabolite of flurazepam. This is a controlled drug precursor therefore a liscence may be required for purchase
Major Application	pharmaceutical
InChI	InChI=1S/C15H10ClFN2O/c16-9-5-6-13-11(7-9)15(18-8-14(20)19-13)10-3-1-2-4-12(10)17/h1-7H,8H2,(H,19,20)
InChIKey	UVCOILFBWYKHHB-UHFFFAOYSA-N
SMILES	N1C2=CC=C(Cl)C=C2C(C2=CC=CC=C2F)=NCC1=O
CAS DataBase Reference	2886-65-9(CAS DataBase Reference)
NIST Chemistry Reference	Norfludiazepam(2886-65-9)

Safety Data

Symbol(GHS)	GHS07
Signal word	Warning
Hazard statements	H336
Precautionary statements	P261-P271-P304+P340+P312-P403+P233-P405-P501
Hazard Codes	F,T
Risk Statements	11-23/24/25-39/23/24/25 less more
Safety Statements	S22:Do not breathe dust . S24/25:Avoid contact with skin and eyes . less more
RIDADR	UN1230 - class 3 - PG 2 - Methanol, solution
WGK Germany	2
RTECS	DF2370100
REACH Registrations	Active
HS Code	2933997500
Storage Class	13 - Non Combustible Solids
Hazard Classifications	STOT SE 3

Hazard Information

Description

Desalkylflurazepam (Item No. 18484) is an analytical reference material that is structurally categorized as a benzodiazepine. It is an active metabolite of several benzodiazepines, including flurazepam (Item No. 18160), flutoprazepam, fludiazepam, midazolam, and quazepam. Desalkylflurazepam inhibits L-type voltage-gated calcium channels (Ca_v; IC₅₀s = 55 and 37 μM for Ca_v1.2 and 1.3, respectively) by positively modulating GABA_A receptors. It can be detected in urine, serum, and meconium by LC-MS/MS. This product is intended for research and forensic applications.

Chemical Properties

Light Yellow Solid

Uses

The major human metabolite of Flurazepam. Controlled substance.

Uses

The major human metabolite of flurazepam. This is a controlled drug precursor therefore a liscence may be required for purchase

Definition

ChEBI: Desalkylflurazepam is a benzodiazepine.

General Description

N-Desalkylflurazepam (also known as norflurazepam, 2886-65-9) is a benzodiazepine analog and an active metabolite of several other benzodiazepine drugs including flurazepam, flutoprazepam, fludiazepam, midazolam, flutazolam, quazepam, and ethyl loflazepate. It is long-acting, prone to accumulation, and binds unselectively to the various benzodiazepine receptor subtypes. It has been sold as a designer drug from 2016 onward.

Mode of action

N-Desalkylflurazepam is a benzodiazepine analog and an active metabolite of several other benzodiazepine drugs including flurazepam, flutoprazepam, fludiazepam, midazolam, flutazolam, quazepam, and ethyl loflazepate. It is long-acting, prone to accumulation, and binds unselectively to the various benzodiazepine receptor subtypes. It has been sold as a designer drug from 2016 onward.

References

[1] DAMIEN E EARL E I T. Inhibition of recombinant L-type voltage-gated calcium channels by positive allosteric modulators of GABAA receptors.[J]. Journal of Pharmacology and Experimental Therapeutics, 2011, 337 1: 301-311. DOI: 10.1124/jpet.110.178244
[2] STEPHANIE J MARIN. Quantitation of benzodiazepines in urine, serum, plasma, and meconium by LC-MS-MS.[J]. Journal of analytical toxicology, 2008, 32 7: 491-498. DOI: 10.1093/jat/32.7.491

Spectrum Detail

Well-known Reagent Company Product Information

Send Inquriy